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median age 65 yrs (range 23-78), male 12 pts, adenocarcinoma 7 pts, 
second-line erlotinib 10 pts, non-smokers 5 pts. Response assessment 
with clinical and/or conventional radiological methods showed 1 partial 
response (PR), 10 progression (PD), 2 stable disease (SD). Three pts 
were too early for response evaluation in this analysis. Overall disease 
control was 23%. All patients were evaluated with FDG-PET before 
erlotinib: mean maximum SUV (SUV-max) and SUV tumor/liver ratio 
was 9 (range 3,5-15) and 5 respectively. Six patients were assessable 
for response with FDG-PET that showed 1 PR, 2 SD and 3 PD. One 
patient with SD on FDG-PET had progression on CT-scan whereas 1 
pt with PD on FDG-PET had SD on CT-scan. As today the follow-up is 
too short to establish the prognostic value of FDG-PET (SUV and SUV 
ratio) in this subset of patients. Accrual is still ongoing and mature 
results will be presented at the XII world conference on lung cancer
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Background: F18-FDG PET/CT provides morphologic and metabolic 
information for diagnosis of malignant disease; however, increased glu-
cose uptake is not exclusive of cancer. We analyzed PET/CT capacity 
to study pulmonary tumors in Chilean population. 
Methods: 204 patients with solitary pulmonary tumors were prospec-
tively included in the study, 91 males, mean age 63.2 years (27-96). 
Exams were performed in a PET-CT Scanner Siemens Biograph 6. We 
studied the group with biopsy and/or follow up longer than 6 months, 
153 of the 204 fulﬁlled this requirements. 66 patients had nodules of 
less than 30 mm and 87 had masses between 31 and 120 mm. Based on 
radiological appearance and metabolic activity in PET/CT, lesions were 
classiﬁed in malignant (112), benign (30) and indeterminate (11).
Results: Malignancy was demonstrated in 106 of 112 lesions catego-
rized as malignant by PET/CT (94.6%); 6 false positive results were 
due to 4 infectious/inﬂammatory lesions and 2 benign carcinoid tumors. 
In the group considered as benign, 3 malignant lesions were demon-
strated by biopsy (10%, 2 metastasis of colorrectal cancer, 1 of thyroid 
cancer). In the indeterminate lesions group, 4 of 11 resulted malignant 
(36.3%, 2 lung cancer, 1 metastasis of kidney cancer and 1 of colic 
cancer). Median SUV Max was 10.5 (1.8-35.9) in the malignant group, 
1.0 (0.3-15.3) in the benign group, and 2.0 g/ml (0.7-5.3) in the indeter-
minate group. Difference on SUV of malignant and benign lesions was 
signiﬁcant. 
Positive predictive value (PPV) for malignancy in the malignant group 
was 94.6%. Malignant lesions were found in the 36.3% of the indeter-
minated group and in the 10% of the benign group. 
Conclusion: F18-FDG PET/CT is a reliable method for the study of 
pulmonary lesions, with a 94.6% positive predictive value for malig-
nancy and 90% of negative predictive value. In the indeterminated 
cases histological study is necessary a (33.6% of malignancy).
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Background: Staging procedures before surgical treatment of non-
small cell lung cancer (NSCLC) usually consist of chest CT scan, 
upper abdomen CT scan or abdomen ultrasound examination, and brain 
CT scan in selected individuals. The clinical suspicion of mediastinal 
lymph nodes involvement (N2 disease) is the indication for mediasti-
noscopy. The aim of the present study was to assess whether preopera-
tive Cyfra 21-1 or CEA serum measurement could help to predict the 
extension of NSCLC before surgery.
Methods: 49 patients (pts), 38 men, 11 women, median age 65 (42-81) 
years referred to the Department of Thoracic Surgery entered this study. 
Mediastinoscopy was performed in 14 pts, lymph node metastases 
were found in 5 pts (further treated with neoadjuvant chemotherapy). 
Primary surgical treatment was performed in 44 pts. Pathologic stage 
of disease was Ia-IIb in 37 pts and IIIa-IV in 7 pts. Cyfra 21-1 and CEA 
were measured with Elecsys Roche in sera collected before any surgi-
cal procedure. 
Results: Cyfra 21-1 values exceeding 3.3 ng/ml were found in 9/37 
pts with stage Ia-IIb and 8/12 pts with stage IIIa-IV (p=0.03). Median 
Cyfra 21-1 value was 1.93 (0.7-7.6) ng/ml in the pts with Ia-IIb stage 
of disease and 4.6 (1.0-14.5) ng/ml in others (p=0.04). 
Median CEA value was 2.59 (0.87-30.9) ng/ml in the pts with stage 
Ia-IIb and 3.17 (0.76-144.2) ng/ml in other pts (nonsigniﬁcant). Median 
CEA value was 13.8 (0.76-144.2) ng/ml in the group of pts with posi-
tive result of mediastinoscopy and 2.6 (1.0-4.81) ng/ml in those with 
negative mediastinoscopy (p=0.0001). 
Conclusion: Serum Cyfra 21-1 elevation before surgery of NSCLC 
may indicate higher pathologic stage of disease, elevated serum CEA is 
possibly predictive for N2 disease, found on mediastinoscopy. 
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Background: Fluorodeoxyglucose-Positron Emission Tomography/
Computed Tomography (FDG-PET/CT) is useful for the diagnosis of 
lung cancer. Accurate diagnosis of pulmonary nodule and lymph node 
metastasis contribute to the decision of treatment. 
Materials and Methods: 324 patients with suspected lung cancer 
was performed FDG-PET/CT Ninety-one tumors of 89 patients 70 
male, 19 female, mean age; 67.7years) were diagnosed histologically 
at Tokushima University Hospital from December 2005 to November 
2006. Standardized uptake value max (SUVmax) was used for evalu-
ation of FDG uptake at early phase and delay phase, and Retention 
Index (RI) was calculated in (SUVmax at delay phase- SUVmax at 
early phase) / SUVmax at early phase X 100 (%). We retrospectively 
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evaluate whether the value of SUVmax and RI can diagnose as lung 
cancer or the presence of lymph node metastasis.
Results: Eighty-one patients were diagnosed as lung cancer and the 
median SUVmax was 9.2 (range, 0.8 to 24). Ten patients were diag-
nosed as benign nodules and the median SUVmax was 3.1 (range, 1.6 
to 8.9). There was a signiﬁcant difference of SUVmax between lung 
cancer and benign tumor (p<0.001). The correlation between tumor 
size in lung cancer and SUVmax were recognized (r=0.67). If the cut-
off value of SUVmax was 3.5 or greater to depict malignant tumors, the 
sensitivity and speciﬁcity in all pulmonary nodules were 84% and 80%. 
The sensitivity and speciﬁcity in tumors more than 3cm in diameter 
were 98% and 100%. On the other hand, in tumors less than 3cm in 
diameter, the sensitivity and speciﬁcity were 48% and 86%. However, 
if the tumor with either RI of more than 10% or SUVmax of more than 
3.5 is classiﬁed as lung cancer, the sensitivity and speciﬁcity was 83% 
and 86% in tumors less than 3cm in diameter. Four hundred and sixty 
lymph nodes of the hilum and the mediastinum were dissected. Twenty-
one of those were metastatic lymph nodes (4.6%). If the lymph nodes 
with 1cm or greater in minor diameter at the chest CT scan are judged 
with metastasis, the sensitivity, speciﬁcity and accuracy were 50%, 
97% and 33%, respectively. Whereas if the cut-off value of SUVmax 
is 3.5 or greater to depict lymph node metastasis at FDG-PET/CT, the 
sensitivity, speciﬁcity and accuracy were 80%, 99% and 76%, respec-
tively. There were 14 false-positive lymph nodes at the chest CT scan 
and 5 false-positive ones at FDG-PET/CT. 
Conclusion: In the tumors more than 3 cm in diameter, the value of 
SUVmax was a very useful tool for diagnosis of lung cancer. However, 
in the tumors less than 3 cm in diameter, the value of RI in addition to 
SUVmax was useful for diagnosis. FDG-PET/CT was signiﬁcantly bet-
ter than the chest CT scan for diagnosis of lymph node metastasis. 
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Background: This systematic review evaluates the accuracy and utility 
of 18Fluorodeoxyglucose positron emission tomography in the diagno-
sis and staging of both non-small cell and small cell lung cancer.
Methods: Relevant health technology assessments, randomized trials 
and meta-analyses were identiﬁed through a systematic search of the 
literature. The Lung Disease Site Group (LDSG) has used the prac-
tice guideline (PG) development cycle described by Browman GP 
et al (JCO 1998; 16(3):1226-31). A unique aspect of the PG is that it 
incorporates practitioner feedback to evaluate the acceptance of the 
guideline among its practitioners.
Results: One high-quality health technology assessment developed by 
the Institute for Clinical and Evaluative Sciences (ICES) in Ontario 
from 2001 was retrieved and formed the basis for this expanded sys-
tematic review. Twelve additional evidence summary reports, including 
meta-analyses, were reviewed. Thirteen additional prospective studies 
of the diagnostic accuracy of PET and three randomized controlled tri-
als evaluating the utility of PET in staging and diagnosis were retrieved 
in a search of the primary literature published following or beyond 
the scope of the ICES report. PET has high sensitivity, and reasonable 
speciﬁcity for differentiating benign from malignant lesions as small 
as 1 cm in size. PET is superior to CT imaging for mediastinal staging 
in NSCLC. PET has not been studied as extensively in patients with 
SCLC, but the available data shows good accuracy in staging extensive 
versus limited disease. Randomized trials reporting on the utility of 
PET report conﬂicting results in terms of the relative reduction in futile 
thoracotomies. Many studies have evaluated the accuracy of 18FDG-
PET in the diagnosis and staging of lung cancer; however there is 
limited evidence to determine the impact of PET on clinically impor-
tant patient outcomes. 
Practitioner feedback was obtained through a series of mail out ques-
tionnaires to stakeholders that included surgical, medical and radiation 
oncologists as well as nuclear medicine physicians. The itemized ques-
tionnaire elicited feedback regarding the rationale for the guideline, 
completeness of the literature search, and acceptance of the methodol-
ogy and recommendations. The percentage of responses that agreed or 
strongly agreed were 80% (rationale for the guideline), 76% (complete-
ness of literature search), 81% (acceptance of methodology), 56% 
(agree with draft recommendations) and 49% (approve as a guideline).
Conclusion: PET has high sensitivity and reasonable speciﬁcity in 
differentiating benign from malignant processes in lung cancer. PET 
may improve results of early-stage lung cancer by excluding patients 
who have evidence of metastatic disease which is beyond the scope of 
surgical resection and is not evident by standard preoperative staging 
procedures. While the systematic review is regarded as a complete and 
thorough summary of the literature, practitioners disagree on the inter-
pretation of the literature and the clinical utility of PET in the manage-
ment of lung cancer.
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Background: This systematic review evaluates the available evidence 
on the role of Positron Emission Tomography (PET) and Co-registered 
Computed Tomography (CT) simulation in radiation treatment planning 
for lung cancer.
Methods: Relevant studies that incorporated PET or gamma cam-
era coincidence imaging (GCCI) into radiation treatment planning 
were identiﬁed through a systematic search of the published clinical 
literature using major electronic indexes (e.g., MEDLINE, EMBASE, 
COCHRANE). 
Results: Twenty-one studies incorporating PET (n=18) or GCCI (n=3) 
into the radiation treatment planning process for patients with lung can-
cer were identiﬁed from 1996 to 2006. Resolution capabilities of PET 
